Biotech firm Odyssey raises $279 million in upsized US IPO
May 7 (Reuters) - Biopharmaceutical company Odyssey Therapeutics has raised $279 million in its upsized U.S. initial public offering, the company said on Thursday. The Boston-based company sold 15.5 million shares at $18 apiece, compared with its marketed range of $16 to $18 per share.